[Cyclooxygenase-2 inhibitors: current concepts (lecture)].
Nasonov
E L
EL
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000201:enzymology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000494:pharmacology*; D008565:Membrane Proteins; D009369:Neoplasms / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control; D010544:Peroxidases / Q000037:antagonists & inhibitors*; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D012333:RNA, Messenger; D010544:Peroxidases; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases